Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E153.56 EPS (ttm)1.09 Insider Own0.50% Shs Outstand75.54M Perf Week15.03%
Market Cap12.64B Forward P/E303.22 EPS next Y0.55 Insider Trans-20.69% Shs Float61.28M Perf Month38.69%
Income86.90M PEG959.75 EPS next Q0.72 Inst Own76.10% Short Float8.43% Perf Quarter37.97%
Sales563.10M P/S22.45 EPS this Y-45.30% Inst Trans-0.16% Short Ratio6.18 Perf Half Y59.68%
Book/sh9.57 P/B17.49 EPS next Y-45.94% ROA10.50% Target Price170.42 Perf Year23.80%
Cash/sh9.75 P/C17.17 EPS next 5Y0.16% ROE13.00% 52W Range82.51 - 167.73 Perf YTD36.90%
Dividend- P/FCF102.96 EPS past 5Y24.50% ROI10.70% 52W High-0.22% Beta0.84
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin94.60% 52W Low102.84% ATR6.31
Employees535 Current Ratio6.00 Sales Q/Q161.80% Oper. Margin45.30% RSI (14)80.10 Volatility5.02% 3.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.60% Profit Margin15.40% Rel Volume1.84 Prev Close167.38
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout0.00% Avg Volume834.77K Price167.36
Recom2.00 SMA2023.32% SMA5023.41% SMA20046.22% Volume1,447,681 Change-0.01%
Oct-17-14Reiterated ROTH Capital Buy $185 → $188
Oct-14-14Reiterated ROTH Capital Buy $183 → $185
Aug-01-14Upgrade WallachBeth Hold → Buy
May-27-14Downgrade RBC Capital Mkts Outperform → Sector Perform $110 → $95
May-05-14Reiterated RBC Capital Mkts Outperform $150 → $110
Feb-21-14Reiterated Deutsche Bank Buy $170 → $180
Dec-18-13Initiated WallachBeth Hold $108
Sep-26-13Initiated Deutsche Bank Buy $170
Dec-12-12Reiterated Wedbush Outperform $93 → $110
Aug-24-12Initiated Stifel Nicolaus Hold
Aug-02-12Downgrade Needham Buy → Hold
May-17-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
May-17-12Reiterated Needham Buy $23 → $32
Feb-21-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
Dec-09-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
Dec-09-11Downgrade Global Hunter Securities Buy → Neutral $15 → $15
Dec-07-11Initiated Rodman & Renshaw Mkt Outperform $20
Nov-11-11Resumed Needham Buy $14
Jun-20-11Reiterated RBC Capital Mkts Outperform $10 → $15
Jun-07-10Reiterated Wedbush Outperform $8 → $16
Jan-23-15 06:34PM  IBD 50 Turns In Solid Week As Market Uptrend Resumes at Investor's Business Daily
04:35PM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:40AM  Why You Shouldn't Bet Against Pharmacyclics (PCYC) Stock - Tale of the Tape Zacks
Jan-20-15 08:43AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
08:36AM  Why Pharmacyclics (PCYC) Could Be Positioned for a Surge? - Tale of the Tape Zacks
Jan-16-15 08:44AM  Can The Uptrend Continue for Pharmacyclics (PCYC)? - Tale of the Tape Zacks
08:02AM  These Top 10 Health Care Funds Are Full Of Vitality at Investor's Business Daily
Jan-15-15 09:30AM  The Zacks Analyst Blog Highlights: NPS Pharmaceuticals, Celgene, Pharmacyclics, Agenus and Incyte - Press Releases Zacks
07:00AM  Pharmacyclics Inc. (PCYC): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-14-15 06:08PM  Nasdaq stocks posting largest percentage increases AP
02:39PM  Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog Zacks
Jan-13-15 01:13PM  Midday movers: Aetna, Ocwen Financial, GoPro & more at CNBC +16.40%
11:29AM  Pharmacyclics Soars As Imbruvica Sales Beat Estimates at Investor's Business Daily
09:29AM  Tuesday Morning Movers: ChannelAdvisor Plummets Benzinga
09:18AM  Ahead of the Bell: Pharmacyclics shares soar AP
06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
Jan-12-15 06:55PM  Alcoa shares rise on earnings, sales beat at MarketWatch
05:45PM  Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook PR Newswire
Jan-07-15 02:51PM  Wells Fargo Top Biotech Stocks for 2015 at 24/7 Wall St.
09:15AM  Analysts 5 Top Momentum Stocks for 2015 With Huge Upside Potential at 24/7 Wall St.
Jan-06-15 10:23AM  Gilead Sciences: Looking Beyond Hepatitis C at Barrons.com
07:38AM  UPDATE: BTIG Initiates Coverage On Pharmacyclics Benzinga
Jan-05-15 09:00AM  IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients PR Newswire
Jan-02-15 04:27PM  At Pharmacyclics, Employees Train To Become Geniuses at Investor's Business Daily
Dec-22-14 09:00AM  Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission PR Newswire
Dec-12-14 09:00AM  Pharmacyclics Named 2014 Outstanding Company by BayBio PR Newswire
Dec-11-14 06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Dec-09-14 04:10PM  Pharmacyclics Presents Imbruvica Data at the ASH Meeting Zacks
02:02PM  UPDATE - IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy PR Newswire
Dec-08-14 09:30PM  IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma PR Newswire
09:01PM  Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL) PR Newswire
08:45PM  IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy PR Newswire
05:50PM  Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks
01:41PM  Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) GlobeNewswire
Dec-06-14 03:01PM  IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma PR Newswire
Dec-05-14 09:00AM  Pharmacyclics Announces Launch of informCLL Registry for Chronic Lymphocytic Leukemia (CLL) Patients PR Newswire
06:45AM  Biotech stocks to watch at ASH CNBC
Dec-04-14 09:00AM  Pharmacyclics Receives 2014 Society for Medicines Research Award for Drug Discovery for Ibrutinib (IMBRUVICA®) PR Newswire
02:24AM  Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) Zacks
Dec-03-14 05:57AM  Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? Zacks
Dec-02-14 05:05PM  Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU Zacks
06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Dec-01-14 09:00AM  New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia PR Newswire
Nov-28-14 06:10AM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-14-14 01:04PM  PHARMACYCLICS INC Financials EDGAR Online Financials
Nov-12-14 04:07PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Nov-09-14 07:09PM  10-Q for Pharmacyclics, Inc. Company Spotlight
Nov-07-14 04:52PM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-06-14 09:29AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
09:09AM  IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting PR Newswire
08:30AM  Keith Lui Joins Versartis to Lead Global Marketing Efforts GlobeNewswire
Nov-05-14 11:00AM  Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca Zacks
Nov-04-14 04:30PM  Pharmacyclics tops Street 3Q forecasts AP
04:13PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:05PM  Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update PR Newswire
02:32PM  AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers PR Newswire
11:00AM  AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors PR Newswire
08:00AM  AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers PR Newswire
07:07AM  Q3 2014 Pharmacyclics Inc Earnings Release - After Market Close CCBN
Oct-22-14 01:40PM  Pharmacyclics Up on Label Expansion Efforts for Imbruvica Zacks
Oct-20-14 08:53AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08:00AM  Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia PR Newswire
Oct-17-14 05:15PM  Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy Zacks
08:49AM  IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers PR Newswire
Oct-16-14 02:45PM  Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia PR Newswire
Oct-14-14 04:20PM  Bristol-Myers Collaborates for Opdivo-Imbruvica Combo Zacks
Oct-13-14 08:00AM  Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma Business Wire
Sep-30-14 04:15PM  PHARMACYCLICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Financial Stateme EDGAR Online
Sep-25-14 04:01PM  Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration PR Newswire
Sep-19-14 12:17PM  Gilead's Zydelig Approved In EU; Imbruvica In Wings at Investor's Business Daily
Sep-11-14 09:30AM  5 Stocks Breaking Out With Big Volume at TheStreet
Sep-08-14 01:02PM  Pharmacyclics Price Target Cut On Higher Spending at Investor's Business Daily
09:10AM  SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks at 24/7 Wall St.
Sep-03-14 06:11PM  Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership Zacks
01:20PM  Infinity Pharma Joins AbbVie On Blood Cancer Drug at Investor's Business Daily
Aug-29-14 04:15PM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Aug-26-14 05:55PM  Celgene, Gilead Lead Big Biotech Stock Movers at Investor's Business Daily
Aug-20-14 07:13AM  Target Expected To Be Right On Target With Earnings Benzinga
Aug-18-14 04:05PM  Pharmacyclics Appoints Chief Commercial Officer PR Newswire
Aug-14-14 03:52PM  PHARMACYCLICS INC Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online
Aug-13-14 10:49AM  Pharmacyclics Has Edge Over Blood Cancer Competitors at TheStreet
Aug-08-14 08:01AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events EDGAR Online
06:05AM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-04-14 06:02AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Aug-01-14 04:10PM  Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales Zacks
12:35PM  Pharmacyclics Q2 Earnings Get Mixed Reception at Investor's Business Daily
10:16AM  The Best Blood Cancer Drug Launch Ever? at Forbes
07:10AM  Pharmacyclics upgraded by WallachBeth Briefing.com
Jul-31-14 04:16PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:04PM  Pharmacyclics Reports Second Quarter 2014 Results PR Newswire
07:07AM  Q2 2014 Pharmacyclics Inc. Earnings Release - After Market Close CCBN
Jul-30-14 01:50PM  5 stocks to watch at MarketWatch
07:35AM  Pharmacyclics (PCYC) Jumps: Stock Rises 15% Zacks
Jul-28-14 07:00PM  Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 PR Newswire
05:00PM  Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval Zacks
01:18PM  U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications PR Newswire
Jul-25-14 08:52AM  European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) for Treatment of Two Blood Cancers PR Newswire
08:32AM  Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger at Motley Fool
Jul-24-14 07:38AM  Can the Rally in Pharmacyclics (PCYC) Shares Continue? Zacks
Jul-23-14 06:11PM  Is Gilead About to Crush Pharmacyclics Stock? at Motley Fool +7.57%
Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghChief Financial OfficerNov 13Option Exercise61.601,00061,60039,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Option Exercise6.843,00020,5206,193Nov 17 04:30 PM
Soni Manmeet SinghChief Financial OfficerNov 13Sale141.441,000141,44238,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Sale141.303,000423,9023,193Nov 17 04:30 PM
Zanganeh MakyChief Operating OfficerNov 12Option Exercise7.195,93142,644216,243Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 12Sale137.965,931818,216210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Option Exercise32.381,50048,5701,705Nov 10 06:30 PM
Zanganeh MakyChief Operating OfficerNov 10Option Exercise2.3023,00052,900233,312Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 10Sale133.8323,0003,078,027210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Sale133.871,500200,805205Nov 10 06:30 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Option Exercise6.845,00034,2008,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerNov 07Option Exercise2.301,5513,567211,863Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 07Sale135.011,551209,401210,312Nov 12 06:07 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Sale134.505,000672,5003,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerSep 04Option Exercise2.305,00011,500215,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 04Sale122.005,000610,000210,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Option Exercise2.307,00016,100217,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Sale121.577,000850,980210,311Sep 04 05:54 PM
Love Richard BGeneral CounselAug 27Option Exercise32.381,50048,5701,704Aug 28 09:52 PM
Love Richard BGeneral CounselAug 27Sale124.001,500186,000204Aug 28 09:52 PM
Tan HeowChief Quality&Tech OperationsAug 21Option Exercise27.052,19659,4024,069Aug 22 02:45 PM
Tan HeowChief Quality&Tech OperationsAug 13Option Exercise27.0510,000270,50011,873Aug 13 05:27 PM
Tan HeowChief Quality&Tech OperationsAug 13Sale123.5810,0001,235,8081,873Aug 13 05:27 PM
McGreivy JesseChief Medical OfficerAug 07Option Exercise73.0934,0622,489,51534,062Aug 07 06:51 PM
McGreivy JesseChief Medical OfficerAug 07Sale120.9234,0624,118,6100Aug 07 06:51 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMay 08Option Exercise25.947,710199,9979,653May 08 06:41 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingApr 29Option Exercise57.162,332133,2972,728May 01 06:14 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Option Exercise6.843,00020,5205,988Mar 07 06:06 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Option Exercise0.8615,00012,90053,004Mar 06 06:06 PM
McGreivy JesseChief Medical OfficerMar 05Option Exercise25.336,563166,2416,563Mar 06 04:35 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Option Exercise25.946,253162,2037,992Mar 06 04:33 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Sale140.756,253880,1151,739Mar 06 04:33 PM
McGreivy JesseChief Medical OfficerMar 05Sale139.666,563916,5990Mar 06 04:35 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Sale140.0015,0002,100,03338,004Mar 06 06:06 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Sale140.503,000421,5042,988Mar 07 06:06 PM
Chang Betty YVP, Research/BiologyMar 04Option Exercise10.2417,500179,23821,254Mar 05 08:15 PM
HALVORSON ERIC HDirectorMar 04Option Exercise17.663,47261,3324,472Mar 06 02:46 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Option Exercise25.9413,747356,59715,486Mar 06 04:33 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Sale137.0713,7471,884,3301,739Mar 06 04:33 PM
HALVORSON ERIC HDirectorMar 04Sale138.333,472480,2821,000Mar 06 02:46 PM
Chang Betty YVP, Research/BiologyMar 04Sale137.9717,5002,414,4843,754Mar 05 08:15 PM
van den Broek RichardDirectorFeb 27Sale144.9225,0003,622,99029,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 26Sale147.1325,6803,778,17054,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 25Sale147.7028,1554,158,49680,290Feb 28 05:26 PM